Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.70 USD

0.70
2,412,764

-0.01 (-0.73%)

Updated May 20, 2019 03:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.08%
18.07%
9.73%
5.25%
2.19%
10.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark

AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.

BAYRY BMY AZN AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark

AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.

AZN BAYRY BMY AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -20.00% and 117.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AVEO Pharmaceuticals (AVEO) closed at $0.91, marking a -1.42% move from the previous day.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?

During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.

AZN AVEO ADRO GILD

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

AVEO Pharmaceuticals (AVEO) closed at $0.92 in the latest trading session, marking a -0.87% move from the prior day.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.

BAYRY AZN AVEO PDLI

Zacks Equity Research

Will AVEO Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

AVEO Pharmaceuticals (AVEO) closed at $1 in the latest trading session, marking a -1.96% move from the prior day.

AVEO

Zacks Equity Research

AVEO (AVEO) Up 71.1% Since Last Earnings Report: Can It Continue?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Outpaces Stock Market Gains: What You Should Know

AVEO Pharmaceuticals (AVEO) closed at $1.10 in the latest trading session, marking a +1.85% move from the prior day.

AVEO

Zacks Equity Research

AVEO Reports Positive Results on Leukemia Drug, Shares Up

AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.

LLY AGIO CELG AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA

AVEO Pharmaceuticals (AVEO) focuses on the NDA for Fotivda in the United States for the treatment of advanced or metastatic RCC.

BAYRY AZN AVEO CELG

Zacks Equity Research

Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO

Zacks Equity Research

Will AVEO Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.

AVEO

Zacks Equity Research

AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?

AVEO (AVEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AVEO

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.

BAYRY AZN CELG AVEO

Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

CELG GILD VRTX AVEO ALKS

Zacks Equity Research

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

CELG VRTX GILD ALKS AVEO REGN

Zacks Equity Research

AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.

BAYRY BMY AVEO GALT

Zacks Equity Research

Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO

Zacks Equity Research

Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO

Kinjel Shah

5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

EXEL AVEO VVUS AMGN INCY GILD ANIK

Zacks Equity Research

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO